Imke Mulder
Chief Tech/Sci/R&D Officer presso 4D PHARMA PLC
Provenienza dei contatti di primo grado di Imke Mulder
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 10 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Imke Mulder tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
| CELGENE | Biotechnology | Chief Tech/Sci/R&D Officer | |
| LIGAND PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
| SANGAMO THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer | |
| H. LUNDBECK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
Metabasis Therapeutics, Inc.
 Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ACTIVE BIOTECH AB | Biotechnology | Director/Board Member | |
| University of Glasgow | College/University | Undergraduate Degree | |
Bristol-Myers Squibb Holdings Ltd.
 Bristol-Myers Squibb Holdings Ltd. MiscellaneousMiscellaneous Part of Bristol Myers Squibb Co., Bristol-Myers Squibb Holdings Ltd. is a holding British company. The private company is based in Uxbridge, UK. | Miscellaneous | Corporate Officer/Principal | |
| University of Leeds | College/University | Doctorate Degree | |
| Queen's University | College/University | Masters Business Admin | |
| Jones International University | College/University | Masters Business Admin | |
| University of Alberta | College/University | Undergraduate Degree | |
| AMBRX INC | Pharmaceuticals: Major | Director/Board Member Chairman | |
| University of Bonn | College/University | Doctorate Degree | |
Speedel Pharma AG
 Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | General Counsel | |
| Philipps University of Marburg | College/University | Doctorate Degree | |
| The Royal College of Physicians | College/University | Corporate Officer/Principal | |
Takeda Pharmaceuticals U.S.A., Inc.
 Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Aquarius Equity Partners Ltd.
 Aquarius Equity Partners Ltd. Investment ManagersFinance Aquarius Equity Partners Ltd is an independent private equity firm founded in the year 2002 by Alan John Aubrey and Duncan Joseph Peyton headquarters in the UK. | Investment Managers | Founder Private Equity Investor | |
GT Biologics Ltd.
 GT Biologics Ltd. Pharmaceuticals: MajorHealth Technology GT Biologics Ltd. manufactures and distributes pharmaceutical products. It develops and commercializes an oral-based probiotic product for the treatment of mild to moderate Crohn's disease and ulcerative colitis and a novel family of protein, peptide therapeutics for the treatment of moderate to severe inflammatory bowel diseases. The company was founded by Denise Kelly in 2008 and is headquartered in Leeds, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
C4X Discovery Ltd.
 C4X Discovery Ltd. Pharmaceuticals: MajorHealth Technology C4X Discovery Ltd. engages in the discovery and development of medical drugs. It uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| North West Seed Fund General Partner Ltd. | Director/Board Member | ||
| Aquarius Origin Fund Managing Member Ltd. | Director/Board Member | ||
| TISSUE REGENIX GROUP PLC | Medical Specialties | Director/Board Member | |
Aquarius Equity Holdings Ltd.
 Aquarius Equity Holdings Ltd. Financial ConglomeratesFinance Aquarius Equity Holdings Ltd. functions as an investment holding British company. The private company is based in Manchester, UK. and has subsidiaries in United Kingdom. | Financial Conglomerates | Director/Board Member | |
| RYVU THERAPEUTICS S.A. | Pharmaceuticals: Major | Director/Board Member | |
| Aquarius Northern Entrepreneurs Managing Member Ltd. | Director/Board Member | ||
Zogenix International Ltd.
 Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin | |
| King's College, Cambridge | College/University | Doctorate Degree | |
| Aquarius Equity Director Ltd. | Director/Board Member | ||
| Aquarius IV Fund Managing Member Ltd. | Director/Board Member | ||
| Aquarius Life Science Ltd. | Director/Board Member | ||
| Schosween 18 Ltd. | Director/Board Member | ||
The Microbiota Co. Ltd.
 The Microbiota Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of 4D Pharma Plc, The Microbiota Co. Ltd. develops a patented bacteria which treats irritable bowel syndrome and related symptoms. The private company is based in Manchester, UK. The Microbiota Co. was acquired by 4D Pharma Plc on July 18, 2014 for $1.65 million. | Pharmaceuticals: Major | Director/Board Member | |
| C4X DISCOVERY HOLDINGS PLC | Pharmaceuticals: Major | Director/Board Member | |
| POSEIDA THERAPEUTICS, INC. | Biotechnology | Corporate Officer/Principal | |
3T Biosciences, Inc.
 3T Biosciences, Inc. BiotechnologyHealth Technology 3T Biosciences, Inc. operates as immunotherapy company. The company was founded by Luke J. Lee, Marvin Gee and Leah Sibener and is headquartered in Palo Alto, CA. | Biotechnology | Corporate Officer/Principal | |
| The Cancer Drug Development Forum | Director/Board Member Director/Board Member | ||
| AG Life Science Consulting Gmbh & Co. Kg | Chief Executive Officer | ||
| Glasmacher Verwaltungs GmbH | Chief Executive Officer | ||
Ambrx Biopharma, Inc.
 Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Biotechnology | Director/Board Member Chairman | |
AvenCell Therapeutics, Inc.
 AvenCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AvenCell Therapeutics, Inc. is a biopharmaceutical company that develops immunotherapies to treat cancers. The private company is based in Cambridge, MA and has subsidiaries in Germany. Andrew D. Schiermeier has been the CEO of the company since 2021. | Pharmaceuticals: Major | Director/Board Member | |
Iqure Pharma, Inc.
 Iqure Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Iqure Pharma, Inc. is a biotech company that develops therapeutics for patients and physicians. The company is based in Wilmington, DE. The company was founded by Pawel Zolnierczyk, Henk de Wilde, Peter Schiemann, Anna Rzewuska. Pawel Zolnierczyk has been the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
Ymmunobio AG
 Ymmunobio AG BiotechnologyHealth Technology Ymmunobio AG is a Swiss preclinical stage oncology biotech company that develops innovative treatments for cancer patients through new classes of antibodies. The company is based in Riehen, Switzerland. The company focuses on high unmet need indications in gastro-intestinal cancers, making extensive progress in developing first-in-class or novel class of antibodies that have the potential to overcome resistance of cancer patients to current available therapies. Ymmunobio's research is based on their deep understanding of immuno-oncology and precision cancer treatments, leveraging their profound knowledge of biologics while selecting the optimal approach to developing transformative therapeutics across cancer indications. The company was founded in 2021 by Katrin Rupalla. The CEO is Peter Schiemann. | Biotechnology | Founder | |
| ZYVERSA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member |
Statistiche
Distribuzione geografica
| Regno Unito | 21 |
| Stati Uniti | 18 |
| Germania | 5 |
| Canada | 3 |
| Svizzera | 3 |
Settori
| Health Technology | 27 |
| Consumer Services | 11 |
| Finance | 3 |
| Miscellaneous | 2 |
| Commercial Services | 2 |
Posizioni
| Director/Board Member | 52 |
| Corporate Officer/Principal | 22 |
| Independent Dir/Board Member | 20 |
| Undergraduate Degree | 8 |
| Founder | 5 |
Contatti più connessi
- Borsa valori
- Insiders
- Imke Mulder
- Connessioni Società
